Procter & Gamble (NYSE:PG) shares dip after 2027 strategy signals nearly 10% hit to earnings
29 July 2026
2 mins read

Procter & Gamble (NYSE:PG) shares dip after 2027 strategy signals nearly 10% hit to earnings

NEW YORK, July 29, 2026, 08:57 EDT

  • Shares were seen down approximately 3% ahead of the market open.
  • Quarterly core profit surpassed expectations, while sales fell short by around $177 million.
  • Initial estimates indicate a 9.7% pre-headwind EPS increase is required at the midpoint of guidance.

Shares of Procter & Gamble declined roughly 3% in premarket trading on Wednesday, as stagnant organic sales and cautious forecasts eclipsed a two-cent earnings beat. The main NYSE session was still yet to begin.

The quarter revealed a divergence between headline growth and core demand. Net sales increased by 2% to $21.2 billion, supported by foreign exchange. Organic sales, as well as volume, pricing and mix, remained unchanged.

Stock chart for NYSE:PG

Core earnings dropped 3% to $1.43 per share, surpassing LSEG’s forecast of $1.41. Revenue fell short of consensus expectations by around $177 million, or 0.8%.

The main worry lies within the fiscal 2027 outlook. P&G projected core EPS in the range of $6.89 to $7.11, with $7.00 as the midpoint. The company revealed total headwinds of $0.56 per share.

An initial arithmetic calculation clarifies the challenge. Moving from $6.89 to $7.00 needs a net increase of $0.11. If a $0.56 headwind is absorbed, this suggests approximately $0.67 in benefits before accounting for the headwind.

This represents 9.7% of core EPS for fiscal 2026. Potential advantages may come from pricing, productivity, and a reduced share count. This estimate does not constitute guidance from the company.

The following comparison is based on company data and LSEG consensus.

MeasureP&G result or outlookComparisonDifference
Q4 net sales$21.203 billion$21.38 billion consensus-$177 million, or -0.8%
Q4 core EPS$1.43$1.41 consensus+$0.02, or +1.4%
FY2027 sales growth midpoint2.0%2.7% consensus-0.7 percentage point
FY2027 core EPS midpoint$7.00$7.04 consensus-$0.04, or -0.6%
Disclosed FY2027 headwinds$0.56 per share$6.89 FY2026 core EPS8.1% drag
Preliminary pre-headwind lift needed$0.67 per share$6.89 FY2026 core EPS9.7%

The challenge comes after an expensive quarter of reinvestment. Core operating margin declined by 130 basis points, even as gross productivity savings reached 460 basis points.

Core selling and administrative expenses increased by 130 basis points as a percentage of sales. Reinvestment in marketing contributed an additional 410 basis points. Productivity gains provided a 300 basis point offset, but this was insufficient.

Chief Executive Shailesh Jejurikar linked the forecast to performance. “Our investments will be funded with a strong productivity program,” he said. Business Wire

Demand remained narrow. Three out of P&G’s five segments reported lower volumes. Health-care segment volumes were down 3%, and both grooming and baby-related categories dropped by 1% each.

Beauty stood out, with volume up 3% and organic sales rising 4%. The other four segments posted either flat or declining organic sales.

Annual results reflected the same trend. Net sales for fiscal 2026 increased by 3% to $87.0 billion. Currency changes accounted for two percentage points of the growth, with pricing making up one point. There was no impact from volume or product mix.

Cash returns continue to provide backing. P&G returned over $15 billion via dividends and share repurchases. The company projects distributing close to $15 billion again in fiscal 2027. Still, projected cash-flow productivity declines to 85%-90% from the previous 100%.

Most of the expected pressure stems from increases in raw-material, energy, and transportation expenses. Chief Financial Officer Andre Schulten described oil as “the biggest variable” in the guidance range. Reuters

Risks: Reduced energy expenses may lessen the $0.56 impact and strengthen the bridge. However, sharper drops in volume or reduced savings might cause earnings to fall short of the midpoint.

TS2 TECH • EXTENDED COVERAGE

Further analysis

What is causing PG shares to decline today?

PG ended Tuesday trading at $148.88, ahead of its fiscal-year update due Wednesday. Early quotes in premarket trading indicated a drop of 2.7% to 3.5%. While core earnings surpassed forecasts, revenue fell short and the company’s fiscal 2027 outlook fell below expectations. Market attention centered on stagnant organic sales and a significant warning on costs. Premarket prices continued to fluctuate. PG Investor

Did P&G surpass forecasts for the fourth quarter?

Core EPS stood at $1.43, beating the consensus of $1.41 by two cents. Net sales totaled $21.20 billion, missing the $21.38 billion forecast. Organic sales were unchanged, while reported sales rose 2%. GAAP EPS declined 15% to $1.26. The quarterly performance was mixed. Procter & Gamble

How soft is P&G’s forecast for fiscal 2027?

Management projects reported and organic sales growth to range from 1% to 3%. Core EPS is forecast between $6.89 and $7.11, with the midpoint at $7.00. That midpoint indicates growth of 1.5% compared to fiscal 2026. According to LSEG, consensus EPS was $7.04, while consensus for sales growth stood at 2.7%. Discontinued portfolio items are expected to reduce organic growth by 30 to 50 basis points. Procter & Gamble

What is the extent of P&G’s pressure on costs and margins?

Management projects a $1 billion net cost from materials, energy and transportation. Interest, reduced non-operating income and currency effects add $350 million more. Altogether, these factors amount to a $0.56 per share impact, an 8% hit to EPS. Fourth-quarter reported operating margin decreased by 220 basis points to 18.6%. Core operating margin slipped 130 basis points for the third quarter in a row. Procter & Gamble

Are P&G’s businesses experiencing a slowdown in consumer demand?

Organic volume across the company was unchanged in the April-to-June period, and prices stayed level as well. Beauty segment volume rose 3%, pushing organic sales up by 4%. In Health Care, volume decreased 3% and organic sales slipped 1%. Organic sales in Baby, Feminine and Family Care fell by 2%. Demand remains uneven, showing limited broad-based momentum. Procter & Gamble

Do dividends and share buybacks provide support for PG shares?

Operating cash flow for fiscal 2026 totaled $19.6 billion. Adjusted free-cash-flow productivity came in at 100%. P&G distributed $10.2 billion via dividends and executed $5.0 billion in share repurchases. The quarterly dividend of $1.0885 translates to an annualized yield near 2.9%. Annualized dividend payments represent around 63% of fiscal 2026 core EPS. Management targets approximately $15 billion in further shareholder returns for fiscal 2027. Procter & Gamble

Does PG look undervalued following its premarket drop?

PG closed Tuesday trading at around 21.8 times trailing earnings. The midpoint for fiscal 2027 suggests a forward core earnings multiple of about 21.3. At the early indication of $144.88, the multiple drops to roughly 20.7 times. As of July 28, XLP’s reported forward multiple was 21.1 times. Analysts’ mean price target stood at $163.61, representing a 9.9% premium over Tuesday’s close. Those targets may be revised after today’s restrained guidance. Barron’s

What key factors should PG shareholders monitor in the upcoming week?

Monitor regular trading following sharp premarket moves. Analyst forecasts and price-target changes are expected after the latest earnings call. Oil price trends are key as management cited a $1 billion cost threat. Shailesh Jejurikar is set to take over as chairman on August 1, centralizing leadership with the CEO role. Jon Moeller steps down from the board July 31 and retires August 14. The main issue remains whether productivity gains can absorb costs without hurting volume. Procter & Gamble

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Google Preferred Source

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY ON WEAKNESS

Visa

NYSE: V 93 / 100
#2 BUY

Hubbell

NYSE: HUBB 92 / 100
#3 BUY ON PULLBACK

Xylem

NYSE: XYL 90 / 100
#4 ACCUMULATE

Ford

NYSE: F 86 / 100
#5 TACTICAL BUY

SoFi

NASDAQ: SOFI 82 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Boston Scientific (NYSE:BSX) shares fall as international growth offsets slower U.S. cardiac performance
Previous Story

Boston Scientific (NYSE:BSX) shares fall as international growth offsets slower U.S. cardiac performance

GE HealthCare shares surge after second-quarter results top forecasts; orders hit new peak
Next Story

GE HealthCare shares surge after second-quarter results top forecasts; orders hit new peak